Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis)
DOI:
https://doi.org/10.2340/actadv.v106.adv-2025-0193Keywords:
Abrocitinib, Atopic Dermatitis, Efficacy, Itch, Minimal Disease Activity, SafetyAbstract
Abrocitinib, an oral selective Janus kinase 1 inhibitor, is approved for the treatment of moderate-tosevere atopic dermatitis (AD) in adults, but realworld evidence remains limited. We retrospectively collected data from 187 adult patients (mean age:37.9 years; 60.4% male), with AD and up to oneyear exposure to abrocitinib either 100 or 200 mg, between 2023 and 2025 across 22 Italian
dermatology centres. Nearly half of patients were bio-experienced and 80 % had difficult-to-treat areas. Beginning at week 8, with either 100 (59%) or 200 mg, 52 % achieved Investigator Global Assessment 0/1, significantly increasing to 88 % at week 52. Similarly, Eczema Area and Severity Index (EASI) and itch had significantly higher 1-year response: increasing from 27.8% and 34.7%, respectively, at week 8, 79.6 % achieved EASI-90 and 73.5% reached Peak Pruritus-Numerical Rating Scale 0/1. Minimal disease activity, a stringent composite endpoint, was met by 18 % at week 8 and by 66 % at week 52. Safety was good, with mild adverse events
mostly including abdominal pain, upper respiratory infections and headache. The 100 mg dose had a significantly better safety profile, with efficacy similar to 200 mg. These data confirm the efficacy and safety of abrocitinib, with early, progressive clinical benefits
sustained through 1 year.
Downloads
References
Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol 2022; 36: 1409–1431. DOI: https://doi.org/10.1111/jdv.18345
Liu H, Dong H, Chen W, Li X, Xiao Z, Li H. Global, regional, and national burden of atopic dermatitis: insights from the Global Burden of Disease Study 2021. Dermatitis 2025. DOI: https://doi.org/10.1177/17103568251365559
JI, Hong HCH, Calimlim BM, Lee WJ, Teixeira HD, Collins EB, et al. Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis without topical corticosteroids: an updated network meta-analysis. Dermatol Ther 2023; 13: 2247–2264. DOI: https://doi.org/10.1007/s13555-023-01000-3
Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol 2022; 36: 1904–1926. DOI: https://doi.org/10.1111/jdv.18429
Simpson EL, Bieber T, Eckert L, Wu R, Ardeleanu M, Graham NMH, et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol 2016; 74: 491–498. DOI: https://doi.org/10.1016/j.jaad.2015.10.043
Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol 2017; 137: 26–30. DOI: https://doi.org/10.1016/j.jid.2016.07.012
Whiteley J, Emir B, Seitzman R, Makinson G. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. Curr Med Res Opin 2016; 32: 1645–1651. DOI: https://doi.org/10.1080/03007995.2016.1195733
Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol 2021; 148: 927–940. DOI: https://doi.org/10.1016/j.jaci.2021.08.009
Gargiulo L, Ibba L, Malagoli P, Burroni AG, Chiricozzi A, Dapavo P, et al. Management of patients affected by moderate-to-severe atopic dermatitis with JAK inhibitors in real-world clinical practice: an Italian Delphi consensus. Dermatol Ther 2024; 14: 919–932. DOI: https://doi.org/10.1007/s13555-024-01135-x
Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebocontrolled, phase 3 trial. Lancet 2020; 396: 255–266. DOI: https://doi.org/10.1016/S0140-6736(20)30732-7
Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, Pink AE, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med 2021; 384: 1101–1112. DOI: https://doi.org/10.1056/NEJMoa2019380
Gargiulo L, Ibba L, Alfano A, Malagoli P, Amoruso F, Balato A, et al. Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study - il AD (Italian landscape atopic dermatitis). J Dermatolog Treat 2024; 35: 2411855. DOI: https://doi.org/10.1080/09546634.2024.2411855
European Medicines Agency. Cibinqo (abrocitinib): summary of product characteristics. 2021. [cited 2025 August 28]. Available from: https: //www.ema.europa.eu/en/documents/ overview/cibinqo-epar-medicine-overview_en.pdf 14. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human participants. JAMA 2025; 333: 71–74. DOI: https://doi.org/10.1001/jama.2024.21972
STROBE statement. [cited 2023 March 1]. Available from: https://www.strobe-statement.org/checklists/cohort-studies
Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbé A, Nelson L, et al. Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol 2019; 181: 761–769. DOI: https://doi.org/10.1111/bjd.17744
Schram ME, Spuls PI, Leeflang MMG, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy 2012; 67: 99–106. DOI: https://doi.org/10.1111/j.1398-9995.2011.02719.x
Silverberg JI, Gooderham M, Katoh N, Aoki V, Pink AE, Binamer Y, et al. Combining treat‐to‐target principles and shared decision‐making: International expert consensus‐based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. Acad Dermatol Venereol 2024; 38: 2139–2148. DOI: https://doi.org/10.1111/jdv.20229
Drucker AM, Morra DE, Prieto-Merino D, Ellis AG, Yiu ZZN, Rochwerg B, et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. JAMA Dermatol 2022; 158: 523–532. DOI: https://doi.org/10.1001/jamadermatol.2022.0455
Ito T, Sugasawa S. Grouped generalized estimating equations for longitudinal data analysis. Biometrics 2023; 79: 1868– 1879. DOI: https://doi.org/10.1111/biom.13718
VY, Bhutani T, Fonacier L, Deleuran M, Shumack S, Valdez H, et al. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND). J Am Acad Dermatol 2022; 87: 351–358. DOI: https://doi.org/10.1016/j.jaad.2022.04.009
Silverberg JI, Simpson EL, Pink AE, Weidinger S, Chan G, Biswas P, et al. Switching from dupilumab to abrocitinib in patients with moderate-to-severe atopic dermatitis: a post hoc analysis of efficacy after treatment with dupilumab in JADE DARE. Dermatol Ther 2025; 15: 367–380. DOI: https://doi.org/10.1007/s13555-024-01320-y
Simpson EL, Silverberg JI, Thyssen JP, Viguier M, Thaçi D, de Bruin-Weller M, et al. Efficacy and safety of abrocitinib in patients with severe and/or difficult-to-treat atopic dermatitis: a post hoc analysis of the randomized phase 3 JADE COMPARE trial. Am J Clin Dermatol 2023; 24: 609–621. DOI: https://doi.org/10.1007/s40257-023-00785-5
Simpson EL, Silverberg JI, Nosbaum A, Winthrop K, Guttman- Yassky E, Hoffmeister KM, et al. Integrated safety update of abrocitinib in 3802 patients with moderate-to-severe atopic dermatitis: data from more than 5200 patient-years with up to 4 years of exposure. Am J Clin Dermatol 2024; 25: 639–654. DOI: https://doi.org/10.1007/s40257-024-00869-w
Tong Z, Zhang Y, Zhou K, Zou Y, Wu Z, Chen J, et al. An observational study of abrocitinib in adults with moderate-tosevere atopic dermatitis after switching from dupilumab. J Am Acad Dermatol 2023; 89: 826–828. DOI: https://doi.org/10.1016/j.jaad.2023.05.077
Olydam JI, Schlösser AR, Custurone P, Nijsten TEC, Hijnen D. Real-world effectiveness of abrocitinib treatment in patients with difficult-to-treat atopic dermatitis. J Eur Acad Dermatol Venereol 2023; 37: 2537–2542. DOI: https://doi.org/10.1111/jdv.19378
Armario-Hita JC, Pereyra-Rodriguez JJ, González-Quesada A, Herranz P, Suarez R, Galan-Gutiérrez M, et al. Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter study. Int J Dermatol 2024; 63: e289–e295. DOI: https://doi.org/10.1111/ijd.17344
Keow S, Abu-Hilal M. Effectiveness of abrocitinib for the treatment of moderate-to-severe atopic dermatitis in patients switched from dupilumab and/or tralokinumab: a real-world retrospective study. J Am Acad Dermatol 2024; 91: 734–735. DOI: https://doi.org/10.1016/j.jaad.2024.05.081
Gargiulo L, Ibba L, Piscazzi F, Alfano A, Cascio Ingurgio R, Valenti M, et al. Effectiveness and safety of upadacitinib for moderate-to-severe atopic dermatitis in a real-world setting: a 52-week retrospective study. J Eur Acad Dermatol Venereol 2024; 38: e152–e154. DOI: https://doi.org/10.1111/jdv.19507
Hu Q, Gao Y, Xu K, Yao X. Drug survival of abrocitinib compared to dupilumab in adult patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2025; 39: e269– e270. DOI: https://doi.org/10.1111/jdv.20265
Ibba L, Falcidia C, Di Giulio S, Bianco M, Valenti M, Facheris P, et al. Real-world effectiveness and safety of upadacitinib and abrocitinib in moderate-to-severe atopic dermatitis: a 52-week retrospective study. J Clin Med 2025; 14: 2953. DOI: https://doi.org/10.3390/jcm14092953
Kim BS, Silverberg JI, Ständer S, Yosipovitch G, Simpson EL, DiBonaventura M, et al. Rapid improvement of itch associated with atopic dermatitis with abrocitinib is partially independent of overall disease improvement: results from pooled phase 2b and 3 monotherapy studies. Dermatitis 2021; 32: S39–S44. DOI: https://doi.org/10.1097/DER.0000000000000770
Additional Files
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
